PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

DOI: 10.1080/15384047.2018.1435221

Keywords: AKT inhibitor, melanoma, mutation, mTOR inhibitor, mTOR serine-threonine kinases, phosphoinositide 3-kinase inhibitor, targeted therapy

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text